Collagenase clostridium histolyticum
- Generic Name
- Collagenase clostridium histolyticum
- Brand Names
- Qwo, Santyl, Xiaflex
- Drug Type
- Biotech
- CAS Number
- 9001-12-1
- Unique Ingredient Identifier
- 9X7O8V25IT
- Background
Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.
On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.
- Indication
Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques. Collagenase ointment is used for the tissue debridement of chronic dermal ulcers and severely burned tissues.
The combination collagenase product, also known as Qwo, is used for the treatment of moderate to severe cellulite in the buttocks of adult women.
- Associated Conditions
- Dupuytren's Contracture of the Hand (Viking's Disease), Peyronie's Disease, Necrotic tissue
Effect of Collagenase on Healing and Scarring
- Conditions
- ScarringImpaired Wound Healing
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-06-09
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 28
- Registration Number
- NCT00651820
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Collagenase in the Treatment of Cellulite
- Conditions
- Cellulite
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 20
- Registration Number
- NCT00261144
- Locations
- 🇺🇸
Dept. Orthopaedics, SUNY Stony Brook, Stony Brook, New York, United States
Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Stony Brook University
- Registration Number
- NCT00261196
- Locations
- 🇺🇸
Dept. Orthopaedics, SUNY@Stony Brook, Stony Brook, New York, United States
Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand
- Conditions
- Adhesion of Flexor Tendon of Hand
- Interventions
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 3
- Registration Number
- NCT00261209
- Locations
- 🇺🇸
Dept. Orthopaedics, SUNY@Stony Brook, Stony Brook, New York, United States
Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease
- Conditions
- Dupuytren's Contracture
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- State University of New York
- Target Recruit Count
- 72
- Registration Number
- NCT00014742
Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
- Conditions
- Dupuytren's Contracture
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- State University of New York
- Target Recruit Count
- 36
- Registration Number
- NCT00004409
- Locations
- 🇺🇸
Stanford University Hospital, Palo Alto, California, United States
🇺🇸State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.